retatrutide data VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide study sees significant weight
Description
Ethics declarations Funding This article was supported by Novo Nordisk
Sweetness and saltiness aren't the only flavors that sometimes turn weird for GLP-1 users
Due to its CNS action, the dual GLP- 1/GIP dual agonist exhibits these superior benefits [23]
These findings indicate that patients who are undergoing GLP-1 therapy may further benefit from this treatment by consuming more dietary fiber, which can be transformed into butyrate in the gut to enhance the beneficial effects of GLP-1
Wed Love to Hear From You
The potential of these drugs to lower risks related to obesity and associated conditions is noteworthy
